FRIDAY, Feb. 4, 2022 (HealthDay News) — You have almost certainly seen the pleas while scrolling through social media: Called crowdfunding, folks try to raise money to pay for their sick loved one’s mounting medical bills. But new research shows these grassroots campaigns rarely raise enough money to make aContinue Reading

FRIDAY, Jan. 21, 2022 (HealthDay News) — Your heart is in an incredibly vulnerable state if you’ve suffered a heart attack or are fighting heart failure, and cardiac rehabilitation could be an important part of your recovery. Unfortunately, not enough older folks appear to be taking advantage of this life-savingContinue Reading

WEDNESDAY, Jan. 19, 2022 (HealthDay News) — Big surprise bills for any colonoscopy done after a positive result from a stool-based screening test will be prevented under new federal rules, a group of U.S. medical organizations say. On Jan. 10, the Biden administration issued guidance requiring private insurers to coverContinue Reading

MONDAY, Jan. 17, 2022 (HealthDay News) — U.S. insurers are paying millions of dollars a year to cover the cost of ivermectin for COVID-19 patients despite a lack of proof the anti-parasitic drug is effective against the virus, a new study finds. Both the U.S. Food and Drug Administration andContinue Reading

TUESDAY, Jan. 11, 2022 (HealthDay News) — It’s a move that could severely limit the number of people taking the controversial new Alzheimer’s drug Aduhelm: Medicare on Tuesday proposed to only cover the cost of the pricey medication for people enrolled in approved clinical trials. A final decision on coverageContinue Reading

MONDAY, Jan. 10, 2022 (HealthDay News) — Medicare has been told to reassess a significant premium increase it had announced that largely stemmed from the expensive new Alzheimer’s drug Aduhelm. U.S. Health and Human Services Secretary Xavier Becerra’s directive, which was announced on Monday, comes shortly after Aduhelm maker BiogenContinue Reading

FRIDAY, Jan. 7, 2022 (HealthDay News) — Following a months-long and unprecedented review, Medicare officials expect to announce within the next couple of weeks whether the program will cover the controversial Alzheimer’s drug Aduhelm. The drug’s benefits are in question and its annual price tag tops $28,000. The U.S. CentersContinue Reading